TVTX · Travere Therapeutics, Inc.

Current Thesis

Travere Therapeutics’ FILSPARI expansion remains a commercial-growth thesis: the next quarterly report must show sales and patient starts exceeding the second quarter, while a weekly close below $58 would invalidate the price structure. The commercial benchmarks are $141.1 million of FILSPARI US net sales and 2,012 patient start forms for Q2 2026, reported on August 4. FILSPARI treats focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN). Travere’s Q2 release.

The narrative is maturing — an inference supported by management’s continued emphasis on the same commercial expansion at the September 10 Cantor conference and the September 18 reference close of $62.76, below the September 4 close of $65.28. The September conference block has elapsed; a newly announced September 24 Stifel appearance supplies another dated disclosure opportunity. Renewed acceleration would require new commercial evidence and a weekly close above the market’s $67.52 reference high. September 10 conference account, September 17 company announcement.

Bullish and bearish views on Travere Therapeutics, Inc.

The model's bull view on Travere Therapeutics, Inc. (TVTX), in brief: Commercial demand has a benchmark. Travere reported Q2 2026 FILSPARI US net sales of $141.1 million, up 96% year over year, and 2,012 patient start forms on August 4. The continuation case requires the next quarter to exceed both figures; failure to do so would reject the… The bear view: Price confirmation has weakened. The September 18, 2026 adjusted reference close was $62.76, with the 14-day relative strength index (RSI) at 41.0. these observations establish weaker momentum, without identifying its cause. Insider supply is observable. FilingExplorer’s… Both cases follow in full.

Bull Case

• Commercial demand has a benchmark. Travere reported Q2 2026 FILSPARI US net sales of $141.1 million, up 96% year over year, and 2,012 patient start forms on August 4. The continuation case requires the next quarter to exceed both figures; failure to do so would reject the proposed repeat-growth test. Q2 results.
• Management reiterated the commercial expansion. At the September 10, 2026 Cantor conference, management described continued IgAN demand and the FSGS launch as growth drivers. This is management’s assessment; the next reported sales and start-form figures must substantiate it. Conference account.

Bear Case

• Price confirmation has weakened. The September 18, 2026 adjusted reference close was $62.76, with the 14-day relative strength index (RSI) at 41.0. these observations establish weaker momentum, without identifying its cause.
• Insider supply is observable. FilingExplorer’s reproduction of chief executive Eric Dube’s Form 4, filed September 18, 2026, records option exercises and sales on September 15–17. Its footnote attributes the sales to a Rule 10b5-1 trading plan adopted June 16, 2026; the transactions do not establish a discretionary response to September business conditions. Form 4 reproduction.
• Commercial growth has not settled profitability. Travere’s August 4, 2026 results reported a Q2 net loss under generally accepted accounting principles of $34.8 million and selling, general and administrative expenses of $96.1 million. A subsequent wider loss alongside flat or lower FILSPARI sales would undermine the operating-leverage case. Q2 results.

Setup & Price Structure

The September 18, 2026 adjusted price series places TVTX 7.0% below its $67.52 trailing-year high, despite a three-month price increase of 13.9%. The $58 weekly-close boundary remains the published structural invalidation level. The $67.52 high is the observable confirmation hurdle; neither level represents a transaction.

The September 18 close is also below the approximately $64.90 initial conversion price disclosed for the convertible notes closed on May 11, 2026. That contractual reference does not establish technical support or prove hedging pressure. No dated moving-average value, short-interest figure or comparable retail-participation series is available here, so crowding cannot be inferred from price alone. The September 18 insider filing establishes supply, not its effect on the market. Dube filing reproduction.

The forecast is modestly favorable rather than strongly favorable: the August 4 commercial results support continuation, while the September 18 price and momentum readings withhold confirmation. For this dossier, the price case plays out on a weekly close above $67.52 before a weekly close below $58; the next quarterly commercial figures separately test the explanation for that move.

Catalyst Calendar (next 30 days)

• 2026-09-24 — Stifel immunology forum. Travere confirmed a management presentation at 10:30 a.m. Eastern Time in its September 17 announcement. Any quantified update could inform the commercial test; the announcement promises a presentation, not new results. Company announcement.
• ~2026-10-22, est. Q3 results. Outside the next 30 days, TipRanks lists October 22 as the next earnings date; this is a third-party calendar indication, not a company-confirmed date. The report is the decisive commercial test against Q2 2026 FILSPARI sales of $141.1 million and 2,012 patient start forms. Third-party calendar, Q2 benchmarks.

What Would Change Our Mind

Loss of the post-August-results structure would end the price thesis: a weekly close below $58 is the observable boundary, retained from the September 6 published assessment. Conversely, a weekly close above the $67.52 reference high before that boundary is breached would complete the stated price case.

The commercial interpretation would fail its continuation test if Q3 2026 FILSPARI US net sales do not exceed $141.1 million or patient start forms do not exceed 2,012, the figures reported August 4. A September 24 presentation without new operating figures would leave that test unresolved; conference attendance alone cannot confirm demand.

Correlation Notes

This remains a single-company commercial setup. The September 20, 2026 coverage context assigns TVTX to no active theme cluster, and no paired return series is available to establish a measured correlation with biotechnology peers. The August 4 sales and patient-start disclosure supplies the company-specific mechanism; a sector move alone would not resolve its next quarterly test.